UnitedHealth Group Incorporated (UNH)
Investors Heavily Search UnitedHealth Group Incorporated (UNH): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.
Focus: UnitedHealth tech unit's rivals say new, post-hack customers are staying
Smaller rivals to UnitedHealth's tech unit Change Healthcare say they are signing longer-term contracts with hospitals and other customers who had temporarily switched from the company after February's cyberattack shut down the unit's services.
UnitedHealth: We See Significant Long-Term Upside
UnitedHealth was our top pick for 2024 due to its strong operating plan and attractive valuation. Despite trailing the S&P 500 by 11%, the stock's long-term potential remains as industry headwinds, like Medicaid and Medicare slowdowns, ease into 2025. UNH's large size and data advantages enable cost-savings and better patient outcomes, making it a strong investment amid rising competitive pressures and regulatory scrutiny.
UnitedHealth Group (UNH) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, UnitedHealth Group (UNH) closed at $589.14, marking a -0.87% move from the previous day.
UnitedHealth Group: Cyberattack Is Manageable, Initiate With A 'Strong Buy'
UnitedHealth's aggressive M&A strategy, including the $13 billion acquisition of Change Healthcare, has strengthened its data analytics and improved margins, justifying a 'Strong Buy' rating. Despite a major cyberattack, UnitedHealth's financial impact is manageable, with expected EPS reduction and increased CAPEX for cybersecurity enhancements. UnitedHealth's divestiture of its Brazilian business reduces FX risk, aligning with its focus on U.S. market growth driven by rising healthcare spending.
What's Behind The 80% Rise In UnitedHealth Stock?
UnitedHealth stock (NYSE: UNH) has gained 80% in value since early January 2021 – jumping from levels of $335 then to around $600 now – vs. an increase of about 45% for the S&P 500 over this period.
UnitedHealth Group: Reaches Near All-Time High But Still Looks Like A 'Buy' (Rating Upgrade)
UnitedHealth Group remains a solid buy-and-hold type of stock for the long-term dividend growth investor. Shares have recently touched a new all-time high; despite that, based on earnings growth going forward, the share price doesn't look overvalued here. Consistent earnings beats could suggest that the shares are also on the cheaper end based on the fair value range, with a chance for double-digit dividend growth to continue.
UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year
UnitedHealth Group said on Tuesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.
UnitedHealth Group (UNH) Stock Dips While Market Gains: Key Facts
UnitedHealth Group (UNH) concluded the recent trading session at $594.10, signifying a -0.47% move from its prior day's close.
Why UnitedHealth Group (UNH) is a Top Stock for the Long-Term
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
3 Reasons UnitedHealth Group Is One of the Best Dividend Stocks You Can Own
UnitedHealth's dividend yield of 1.4% looks modest but not when you factor in its growth. The company has nearly doubled its payout in just five years.
UnitedHealth Group (UNH) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, UnitedHealth Group (UNH) closed at $598.68, indicating a +1.44% shift from the previous trading day.
